Clinical features of anti-amphiphysin positive patients with paraneoplastic neurological disorders
Patient | Age/sex | Clinical syndrome | Hu-Ab | Time (months) PND/tumour | Cancer | Outcome |
---|---|---|---|---|---|---|
1 | 60/F | Sensorimotor neuropathy | Yes | −23 | SCLC | Necropsy: PEM/SN1-151 |
2 | 58/M | PEM/SN | Yes | −7 | SCLC | Necropsy: PEM/SN1-151 |
3 | 71/M | PEM/SN and LEMS | Yes | −17 | SCLC | Necropsy: PEM/SN1-151 |
4 | 64/M | Sensory neuropathy | No1-150 | 0 | SCLC | Death: pulmonary embolus |
5 | 64/M | Cerebellar syndrome | No | −18 | SCLC | Alive for 7 years |
6 | 74/M | Opsoclonus/myoclonus | No1-150 | −1 | SCLC | Necropsy: perivascular/meningeal inflammatory infiltrates. Moderate neuronal loss in dentate nucleus and Purkinje cells |
7 | 80/F | Sensory neuropathy | Yes | n.a. | None | Necropsy: PEM/SN** |
PEM/SN=Paraneoplastic encephalomyelitis/sensory neuronopathy; LEMS=Lambert-Eaton myasthenic syndrome; SCLC=small cell lung carcinoma; NA=not applicable.
↵1-150 Patients had low titre of Hu-Ab similar to that found in 16% of SCLC without paraneoplastic neurological disorders.11
↵1-151 Necropsy findings typical of PEM/SN with multifocal inflammatory infiltrates, reactive gliosis, and neuronal loss.